Patents by Inventor John Francis Martin

John Francis Martin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11933880
    Abstract: An implement for use with an excavator includes a lightweight housing, a first coupling feature, a ground penetrating radar antenna, a controller, a wireless communication circuit and a rotation unit. The lightweight housing has an upper surface, a lower surface and a cavity. The first coupling feature is located on the upper surface and cooperates with a second coupling feature on an excavator arm. The ground penetrating radar antenna is mounted near the lower surface. The controller is mounted within the cavity and provides outgoing signals to the radar antenna, receives incoming signals from the radar antenna and interprets the incoming signals so as to provide implement output information. The wireless communication circuit is mounted within the cavity and transmits the implement output information. The rotation unit is mounted within the cavity and rotates the housing vis-à-vis the excavator arm.
    Type: Grant
    Filed: August 2, 2020
    Date of Patent: March 19, 2024
    Assignee: RodRadar Ltd.
    Inventors: Simon Conway, Thomas James Martin, John Francis Roulston
  • Publication number: 20230128372
    Abstract: The present invention relates to AZD1656 or a pharmaceutically acceptable salt thereof, for use in the treatment of pneumonitis and/or myocarditis, which may be associated with or caused by a coronavirus infection.
    Type: Application
    Filed: March 12, 2021
    Publication date: April 27, 2023
    Inventor: John Francis MARTIN
  • Patent number: 11191877
    Abstract: A biosorbable magnetisable endoprosthesis, may be useful in the therapy of restenosis. A method for the treatment of prevention of restenosis or a disease of the coronary artery, comprises fitting a patent with an endoprosthesis according to the invention, which has either been magnetized prior to placement in the body or which is magnetized in situ, and administering to the patient magnetized cells capable of repairing an artery.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: December 7, 2021
    Assignee: MAGNUS FLOW LIMITED
    Inventors: John Francis Martin, Anthony Mathur
  • Patent number: 10478455
    Abstract: Tetrathiomolybdate is for use in therapy of a condition requiring reduced metabolism of an organ or whole body, e.g. myocardial infection, stroke or ischaemia-reperfusion injury.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: November 19, 2019
    Assignee: UCL BUSINESS LTD
    Inventors: Mervyn Singer, John Francis Martin, Alex Peter Dyson
  • Publication number: 20190117854
    Abstract: A biosorbable magnetisable endoprosthesis, may be useful in the therapy of restenosis. A method for the treatment of prevention of restenosis or a disease of the coronary artery, comprises fitting a patent with an endoprosthesis according to the invention, which has either been magnetized prior to placement in the body or which is magnetized in situ, and administering to the patient magnetized cells capable of repairing an artery.
    Type: Application
    Filed: October 19, 2018
    Publication date: April 25, 2019
    Applicant: MAGNUS FLOW LIMITED
    Inventors: John Francis MARTIN, Anthony MATHUR
  • Publication number: 20170119849
    Abstract: The present invention provides a composition comprising cells obtainable by bone marrow aspiration, or multipotent or pluripotent progenitor cells, and granulocyte-colony stimulating factor (G-CSF), as a combined preparation for simultaneous, separate or sequential use in the therapy of cardiomyopathy in a subject, wherein the cells are administered directly to the myocardium of the subject.
    Type: Application
    Filed: June 10, 2015
    Publication date: May 4, 2017
    Inventors: Anthony MATHUR, John Francis MARTIN
  • Publication number: 20140324158
    Abstract: A biosorbable magnetisable endoprosthesis, may be useful in the therapy of restenosis. A method for the treatment of prevention of restenosis or a disease of thecoronary artery, comprises fitting a patent with an endoprosthesis according to the invention, which has either been magnetized prior to placement in the body or which is magnetized in situ, and administering to the patient magnetized cells capable of repairing an artery.
    Type: Application
    Filed: October 1, 2012
    Publication date: October 30, 2014
    Applicant: MAGNUS STENT IC
    Inventors: John Francis Martin, Anthony Mathur
  • Publication number: 20140121160
    Abstract: An agonist of the VEGF receptor is useful in the treatment of a disease associated with retarded fetal growth, such as intra-uterine growth retardation. The VEGF against may be a VEGF peptide or a gene construct encoding or expressing such a PI-peptide.
    Type: Application
    Filed: October 29, 2012
    Publication date: May 1, 2014
    Inventors: John Francis MARTIN, Charles Henry RODECK
  • Publication number: 20140045907
    Abstract: It has been found that inhibitors of the rennin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia or impaired metabolic function or efficiency. In particular, they may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and the treatment or prevention of wasting or cachexia, and are thus useful in treatment of the symptoms and signs of aging. These inhibitors may also be used to enhance function in healthy subjects.
    Type: Application
    Filed: October 21, 2013
    Publication date: February 13, 2014
    Applicant: FinVector Vision Therapies Ltd
    Inventors: Hugh Edward MONTGOMERY, John Francis Martin, Jorge Daniel Erusalimsky
  • Patent number: 8604070
    Abstract: It has been found that inhibitors of the rennin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia or impaired metabolic function or efficiency. In particular, they may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and the treatment or prevention of wasting or cachexia, and are thus useful in treatment of the symptoms and signs of aging. These inhibitors may also be used to enhance function in healthy subjects.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: December 10, 2013
    Assignee: FinVector Vision Therapies, Ltd.
    Inventors: Hugh Edward Montgomery, John Francis Martin, Jorge Daniel Erusalimsky
  • Publication number: 20130097014
    Abstract: Two digital files are combined through an automatic process to create a third digital combination file. A media file is uploaded to a media file database and an advertising file is uploaded to an advertising database. A first advertising file is selected to be combined with a second media file using smart logic and analysis. The selected first advertising file and second media file are automatically combined to create a third, new, unitary combination file. The third new combination file is then made available to consumers/end users through download or streaming without charge. The artists who provide the media files may be compensated according to the number of times each of their songs/media are downloaded or streamed by a consumer/end user.
    Type: Application
    Filed: April 3, 2012
    Publication date: April 18, 2013
    Applicant: AUXILIARY BAY , LLC
    Inventors: John Francis Martin, Chaitanya Dalvi
  • Patent number: 8334271
    Abstract: An agonist of the VEGF receptor is useful in the treatment of a disease associated with retarded fetal growth, such as intra-uterine growth retardation. The VEGF agonist may be a VEGF peptide or a gene construct encoding or expressing such a peptide.
    Type: Grant
    Filed: February 22, 2008
    Date of Patent: December 18, 2012
    Assignee: Ark Therapeutics, Ltd.
    Inventors: John Francis Martin, Charles Henry Rodeck
  • Publication number: 20120308522
    Abstract: Vascular endothelial growth factor (VEGF) has utility in the treatment of intimal hyperplasia, hypertension and atherosclerosis, and of conditions susceptible to treatment with agents that produce nitric oxide or prostacyclin. Instead of VEGF, an equivalent agent such as an agonist of VEGF receptors may be given, as may nucleic acid encoding such an agonist. The agent may successfully be administered via the adventitial surface of a blood vessel, e.g. using a device which defines a reservoir between the body wall and the vessel's adventitial surface, the reservoir being at least part-filled by a pharmaceutical formulation containing the agent to be delivered.
    Type: Application
    Filed: June 27, 2012
    Publication date: December 6, 2012
    Inventors: John Francis MARTIN, Seppo Yla-Herttuala, Stephen George Edward Barker
  • Publication number: 20120178784
    Abstract: It has been found that inhibitors of the rennin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia or impaired metabolic function or efficiency. In particular, they may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and the treatment or prevention of wasting or cachexia, and are thus useful in treatment of the symptoms and signs of aging. These inhibitors may also be used to enhance function in healthy subjects.
    Type: Application
    Filed: January 30, 2012
    Publication date: July 12, 2012
    Inventors: Hugh Edward Montgomery, John Francis Martin, Jorge Daniel Erusalimsky
  • Patent number: 8003679
    Abstract: Inhibitors of the rennin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia, such as stroke.
    Type: Grant
    Filed: May 25, 2006
    Date of Patent: August 23, 2011
    Assignee: ArkTherapeutics Group, plc
    Inventors: Hugh Edward Montgomery, John Francis Martin, Jorge Daniel Erusalimsky
  • Patent number: 7998953
    Abstract: It has been found that inhibitors of the rennin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia or impaired metabolic function or efficiency. In particular, they may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and the treatment or prevention of wasting or cachexia, and are thus useful in treatment of the symptoms and signs of aging. These inhibitors may also be used to enhance function in healthy subjects.
    Type: Grant
    Filed: April 29, 2005
    Date of Patent: August 16, 2011
    Assignee: Ark Therapeutics Group, p.l.c.
    Inventors: Hugh Edward Montgomery, John Francis Martin, Jorge Daniel Erusalimsky
  • Publication number: 20100249015
    Abstract: An agonist of the VEGF receptor is useful in the treatment of a disease associated with retarded fetal growth, such as intra-uterine growth retardation. The VEGF against may be a VEGF peptide or a gene construct encoding or expressing such a peptide.
    Type: Application
    Filed: February 22, 2008
    Publication date: September 30, 2010
    Inventors: John Francis Martin, Charles Henry Martin, John Francis Martin, Charles Henry Rodeck
  • Publication number: 20090069348
    Abstract: It has been found that an inhibitor of the renin-angiotensin system is useful for the treatment or prevention of a condition associated with hypoxia or impaired metabolic function or efficiency. In particular, it may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and the treatment or prevention of wasting or cachexia, and is thus useful in treatment of the symptoms and signs of ageing. It may also be used to enhance function in healthy subjects.
    Type: Application
    Filed: September 5, 2008
    Publication date: March 12, 2009
    Inventors: Hugh Edward Montgomery, John Francis Martin, Jorge Daniel Erusalimsky
  • Publication number: 20080305999
    Abstract: Vascular endothelial growth factor (VEGF) has utility in the treatment of intimal hyperplasia, hypertension and atherosclerosis, and of conditions susceptible to treatment with agents that produce nitric oxide or prostacyclin. Instead of VEGF, an equivalent agent such as an agonist of VEGF receptors may be given, as may nucleic acid encoding such an agonist. The agent may successfully be administered via the adventitial surface of a blood vessel, e.g. using a device which defines a reservoir between the body wall and the vessel's adventitial surface, the reservoir being at least part-filled by a pharmaceutical formulation containing the agent to be delivered.
    Type: Application
    Filed: November 20, 2007
    Publication date: December 11, 2008
    Inventors: John Francis Martin, Seppo Yla-Herttuala, Stephen George Edward Barker
  • Patent number: 7320679
    Abstract: The present invention concerns vascular endothelial growth factor (VEGF) which has utility in the treatment of intimal hyperplasia, hypertension and atherosclerosis, and of conditions susceptible to treatment with agents that produce nitric oxide or prostacyclin. Instead of VEGF, an equivalent agent such as an agonist of VEGF receptors may be given, as may nucleic acid encoding such an agonist. The agent may successfully be administered via the adventitial surface of a blood vessel, e.g., using a device which defines a reservoir between the body wall and the vessel's adventitial surface, the reservoir being at least part-filled by a pharmaceutical formulation containing the agent to be delivered.
    Type: Grant
    Filed: February 19, 2003
    Date of Patent: January 22, 2008
    Assignee: Ark Therapeutics, Ltd.
    Inventors: John Francis Martin, Seppo Yla-Herttuala, Stephen George Edward Barker